Purpose Patients with pathological stage T1N+ or T2–3N0 gastric cancer may experience disease recurrence following curative gastrectomy. However, the current Japanese Gastric Cancer Treatment Guidelines do not recommend postoperative adjuvant chemotherapy for such patients. This study aimed to identify the prognostic factors for patients with pT1N+ or pT2–3N0 gastric cancer using a multi-institutional dataset. Materials and Methods We retrospectively analyzed the data obtained from 401 patients with pT1N+ or pT2–3N0 gastric cancer who underwent curative gastrectomy at 9 institutions between 2010 and 2014. Results Of the 401 patients assessed, 24 (6.0%) experienced postoperative disease recurrence. Multivariate analysis revealed that age ≥70 years (hazard ratio [HR], 2.62; 95% confidence interval [CI], 1.09–7.23; P=0.030) and lymphatic and/or venous invasion (lymphovascular invasion (LVI): HR, 7.88; 95% CI, 1.66–140.9; P=0.005) were independent prognostic factors for poor recurrence-free survival. There was no significant association between LVI and the site of initial recurrence. Conclusions LVI is an indicator of poor prognosis in patients with pT1N+ or pT2–3N0 gastric cancer.

中文翻译：

---

pT1N+ 或 pT2-3N0 胃癌患者淋巴血管浸润与复发之间的关联：多机构数据集分析

目的 病理分期为 T1N+ 或 T2-3N0 的胃癌患者在根治性胃切除术后可能会出现疾病复发。但是，现行的日本胃癌治疗指南不建议对此类患者进行术后辅助化疗。本研究旨在使用多机构数据集确定 pT1N+ 或 pT2-3N0 胃癌患者的预后因素。材料和方法 我们回顾性分析了 2010 年至 2014 年间在 9 家机构接受根治性胃切除术的 401 例 pT1N+ 或 pT2-3N0 胃癌患者的数据。结果在评估的 401 例患者中，24 例（6.0%）发生术后疾病复发。多变量分析显示，年龄≥70 岁（风险比 [HR]，2.62；95% 置信区间 [CI]，1.09-7.23；P=0。030）和淋巴和/或静脉侵犯（淋巴血管侵犯（LVI）：HR，7.88；95% CI，1.66-140.9；P=0.005）是无复发生存率差的独立预后因素。LVI 与初始复发部位之间没有显着关联。结论 LVI是pT1N+或pT2-3N0胃癌患者预后不良的指标。